ArticleScientific reports2025
Cancer-associated fibroblast subtype and risk signature as predictors of prognosis and treatment effectiveness in gastric cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Transcriptomic Analysis and Machine Learning Identify THY1 as a Key Regulator of Cancer-Associated Fibroblast Infiltration, Promoting Malignant Progression and Immune Escape in Gastric Cancer.Journal of gastroenterology and hepatology · 2026Article
- Immunotherapy rechallenge in gastric cancer: resistance mechanisms, molecular stratification, and precision decision-making.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite the persistent high incidence and mortality rates of gastric cancer, limited progress has been made in improving prognosis.cancer-associated fibroblasts (CAFs) hold promise as novel biomarkers, yet their specific roles and mechanisms in gastric cancer remain enigmatic. We utilized the TCGA-STAD dataset for model training and the GSE84433 dataset for validation to explore potential associations between cancer-associated fibroblasts (CAFs) and clinical outcomes in gastric cancer. Through consensus clustering, differential expression analysis, enrichment analysis, and immune infiltration assessment, Kaplan-Meier (KM) survival analysis, and TIMER database exploration, we examined the prognostic significance and underlying biological mechanisms of CAF-related genes in gastric cancer. A CAF risk model (CAF-RM) was developed to assess the correlation between risk scores and survival, drug sensitivity, and immune infiltration. The model was further validated through immunohistochemical (IHC) and immunofluorescence (IF) staining. Utilizing data from 42 CAF-related genes, consensus clustering identified two distinct patient subgroups, C1 and C2, with significant differences in survival, immune scores, and immune cell infiltration. A Cox-Lasso regression-derived CAF-RM accurately discriminated high-risk from low-risk gastric cancer patients, consistent with validation cohort results, IHC and IF staining. These findings suggest that CAFs play a role in the tumor immune microenvironment of gastric cancer and highlight the efficacy of CAF-RM in prognosis prediction. CAF subtypes associate with immune tumor microenvironment alterations in gastric cancer. The validated CAF risk model predicts patient survival, immune infiltration, and drug sensitivity, enhancing understanding of CAFs and guiding gastric cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.